Mollinedo F, Gajate C, Flores I
Center for Biological Research, Superior Council of Scientific Research, Madrid, Spain.
J Immunol. 1994 Sep 15;153(6):2457-69.
The induction of the AP-1 transcription factor has been ascribed to the early events leading to T lymphocyte activation. We have examined the possibility that stimulation of phospholipase D (PLD) may regulate activation of transcription factor AP-1 in human T cells by transfecting human T lymphocyte Jurkat cells with a plasmid containing an AP-1 enhancer element and a chloramphenicol acetyltransferase reporter gene. We have detected activatable PLD in Jurkat cells, and we have found that addition of phosphatidic acid (PA), the physiologic product of PLD action on phospholipids, is rapidly incorporated into Jurkat cells and leads to activation of transcription factor AP-1. Treatment of Jurkat cells with anti-CD3 mAb activated both PLD and transcription factor AP-1. Wortmannin, an inhibitor of receptor-coupled PLD activation, blocked the anti-CD3-induced increases in both PLD activity and AP-1 enhancer activity. We found a good correlation in the transfected cells between PLD activation and induction of AP-1 enhancer activity under different experimental conditions. Furthermore, ethanol, an inhibitor of the PLD pathway, blocked the anti-CD3-stimulated AP-1 enhancer activity. However, this anti-CD3-mediated response was not inhibited by neomycin, an inhibitor of phosphoinositide hydrolysis. The increases in AP-1 enhancer activity induced by PA or anti-CD3 mAb were efficiently abrogated by the presence of propranolol, an inhibitor of PA phosphohydrolase and protein kinase C (PKC). Furthermore, the PA- and the anti-CD3-induced increases in AP-1 enhancer activity were blocked by the presence of PKC inhibitors or by PKC down-regulation. These data indicate that PLD stimulation can activate the transcription factor AP-1 in T lymphocytes, and suggest that the induction of AP-1 enhancer factor activity by PA is mediated via PKC stimulation, either through a direct activating effect of PA or through PA-derived diacylglycerol formation. These data also provide evidence for a role of PLD-derived lipids in the induction of AP-1 enhancer activity resulting from stimulation of the TCR/CD3 complex, suggesting that increased PLD activity can play an important role in T lymphocyte activation.
AP-1转录因子的诱导作用已归因于导致T淋巴细胞活化的早期事件。我们通过用含有AP-1增强子元件和氯霉素乙酰转移酶报告基因的质粒转染人T淋巴细胞Jurkat细胞,研究了磷脂酶D(PLD)刺激可能调节人T细胞中转录因子AP-1活化的可能性。我们在Jurkat细胞中检测到了可激活的PLD,并且发现添加磷脂酸(PA),即PLD作用于磷脂的生理产物,可迅速被Jurkat细胞摄取并导致转录因子AP-1的活化。用抗CD3单克隆抗体处理Jurkat细胞可激活PLD和转录因子AP-1。渥曼青霉素,一种受体偶联的PLD活化抑制剂,可阻断抗CD3诱导的PLD活性和AP-1增强子活性的增加。我们发现在不同实验条件下,转染细胞中PLD活化与AP-1增强子活性的诱导之间存在良好的相关性。此外,乙醇,一种PLD途径的抑制剂,可阻断抗CD3刺激的AP-1增强子活性。然而,这种抗CD3介导的反应不受新霉素的抑制,新霉素是一种磷酸肌醇水解抑制剂。PA或抗CD3单克隆抗体诱导的AP-1增强子活性的增加被普萘洛尔有效消除,普萘洛尔是一种PA磷酸水解酶和蛋白激酶C(PKC)的抑制剂。此外,PA和抗CD3诱导的AP-1增强子活性的增加被PKC抑制剂的存在或PKC下调所阻断。这些数据表明PLD刺激可激活T淋巴细胞中的转录因子AP-1,并表明PA诱导的AP-1增强子因子活性是通过PKC刺激介导的,要么是通过PA的直接激活作用,要么是通过PA衍生的二酰基甘油的形成。这些数据还为PLD衍生的脂质在TCR/CD3复合物刺激导致的AP-1增强子活性诱导中的作用提供了证据,表明PLD活性的增加在T淋巴细胞活化中可能起重要作用。